Paper
0
Prognostic relevance of CD163+ immune cells in patients with metastatic breast cancer
Authors
Published
Jan 3, 2025
Show more
Save
Tip0
TipSave
Abstract
Metastatic breast cancer (MBC) is generally considered an incurable disease and even though new treatments are available, the median survival is approximately three years. The introduction of immune therapies for MBC highlights the importance of the immune system in cancer progression and treatment. CD163
Paper PDF
This PDF hasn't been uploaded yet.
Do not upload any copyrighted content to the site, only open-access content.
or